Table 2.

Associations between serial glycemic parameters over time and ICU mortality

	mean glucose					maximum glucose difference
Model 1: Crude	β mmol/l	CI (95%) mmol/l	β mg/dl	CI (95%) mg/dl	p-value	β mmol/l	CI (95%) mmol/l	β mg/dl	CI (95%) mg/dl	p-value
ICU-survivors (reference)	-	-			-	-	-			-
Mortality	0.67	0.25; 1.10	12.1	4.5; 19.8	0.002	0.86	0.38; 1.34	15.4	6.84; 24.12	< 0.001
time * ICU non-survivors (slope)	-0.06	-0.08; -0.04	-1.08	-1.44; 0.72	< 0.001	-0.03	-0.05; -0.01	0.54	-0.9; -0,18	0.001
Model 2*: Adjusted
ICU-survivors (reference)	-	-	-	-	-	-	-	-	-	-
Mortality	0.64	0.21; 1.07	11.5	3.8; 19.3	0.003	0.87	0.39; 1.35	15.7	7.02; 24.3	< 0.001
time * ICU non-survivors (slope)	-0.06	-0.08; -0.04	-1.1	-1.44; -0.72	< 0.001	-0.03	-0.05; -0.01	-0.54	0.9; 0.18	0.007

β (95% CI) indicates the regression coefficient, or difference and slope over time of mean glucose (mmol/l and mg/dl) and maximum glucose (in mmol/l and mg/dl ) difference per day, respectively, for ICU non-survivors, with ICU survivors as reference. Model 1: Crude analysis. Model 2: adjusted for age, sex, body mass index (BMI) and APACHE II score, chronic kidney, pulmonary and liver diseases, and cardiovascular risk factors

CI: Confidence Interval, ICU: Intensive Care Unit;

*Data on BMI (n = 3) and cardiovascular risk factors (n = 3) were missing; hence model 2 included 226